Why Scrip Awards Have Shortlisted orphan reach, a CRO That Develops Drugs for Rare Diseases

The media attention will hopefully raise more awareness of patients with a rare disease.

The finalists of this year’s 13th annual Scrip Awards, the “Oscars of the biopharmaceutical industry”, have just been announced with one particular category likely to draw some attention: “Best Contract Research Organization – Specialist Providers. orphan reach, a CRO exclusively focused on the clinical development of new therapies to treat rare diseases, has been shortlisted as one of 6 companies and is the first such organization to be nominated in this category.

Over the summer, a panel of 16 respected judges has reviewed all entries to produce a shortlist that displays the wealth of innovation, dedication and hard work that the pharmaceutical and biotech industries have shown over the past year. The full range of industry activities from big pharma, biotech companies and CROs is represented: from novel deals, to new drug launches and finding technological breakthroughs in clinical trials. The Scrip Awards provides the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement.

“We are very honoured to have been considered for this prestigious award” says orphan reach’s Chief Executive Officer, Thomas Ogorka. “Most of all, the media attention will hopefully help to raise more awareness of the desperate situation that many patients with a rare disease and their families have to deal with every day. With more than 7,000 rare diseases of which fewer than 5% have drug therapies available, there is much more that our industry must and can do. orphan reach has been created to accelerate the development of new orphan drugs and to accommodate…

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *